Results 111 to 120 of about 8,073 (209)

Systemic and metabolic effects of PDE5-inhibitor drugs

World Journal of Diabetes, 2010
Phosphodiesterase type-5 inhibitor (PDE5-i) drugs were first marketed in 1998 (sildenafil) for 'ondemand' treatment of male erectile dysfunction (ED) of any origin. They selectively inhibit intrapenile PDE5 isoenzyme which in turn increases intracellular cyclic guanosine monophosphate levels, thus resulting in prolonged relaxation of cavernosum smooth ...
openaire   +2 more sources

Design, synthesis and development of PDE5 inhibitors [PDF]

, 2009
This research project is concerned with the design, synthesis and development of new phosphodiesterase 5 (PDE5) inhibitors with improved selectivities and lower toxicities.
Wang, Guocheng
core  

Unmasking hidden risks: The surprising link between PDE5 inhibitors and seizure susceptibility. [PDF]

PLoS One, 2023
Silva ALMD, Nascimento CP, Azevedo JEC, Vieira LR, Hamoy AO, Tiago ACDS, Martins Rodrigues JC, de Araujo DB, Favacho Lopes DC, de Mello VJ, Hamoy M.   +10 more
europepmc   +1 more source

Phosphodiesterase-5 inhibitors: Raynaud's and beyond

Indian Journal of Rheumatology, 2017
Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak, Sajal Ajmani, Vikas Agarwal, Durga Prasanna Misra   +3 more
doaj  

Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy. [PDF]

J Sex Med, 2023
Furtado TP, Miranda EP, Deveci S, Jenkins L, Narus J, Nelson C, Mulhall JP.   +6 more
europepmc   +1 more source

Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism [PDF]

Purpose Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated.
Guangdong Hou, Ming Gao, Fu Wang, Jun Guo, Zheng Li, Jianlin Yuan, Yan Zhang, Chunlin Wang, Hui Zhang   +8 more
core   +1 more source

The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders. [PDF]

J Thromb Haemost, 2022
Degjoni A, Campolo F, Stefanini L, Venneri MA.   +3 more
europepmc   +1 more source

Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties. [PDF]

Pharmaceutics, 2022
Amin KM, El-Badry OM, Abdel Rahman DE, Abdellattif MH, Abourehab MAS, El-Maghrabey MH, Elsaid FG, El Hamd MA, Elkamhawy A, Ammar UM.   +9 more
europepmc   +1 more source

Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors - Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP. [PDF]

Front Physiol, 2021
Selli AL, Kuzmiszyn AK, Smaglyukova N, Kondratiev TV, Fuskevåg OM, Lyså RA, Ravna AW, Tveita T, Sager G, Dietrichs ES.   +9 more
europepmc   +1 more source

Future prospects in the treatment of erectile dysfunction: focus on avanafil

Drug Design, Development and Therapy, 2011
Amjad Alwaal, Raed Al-Mannie, Serge Carrier Division of Urology, McGill University Health Centre, Montreal, Quebec, Canada Abstract: The treatment of erectile dysfunction (ED) has been revolutionized in the last 15 years with the introduction of type 5 ...
Alwaal A, Al-Mannie R, Carrier S
doaj